COVID-19 Press Briefing

March 3, 2021
Daily Change in COVID-19 Cases, US
January 22, 2020 – March 1, 2021

TOTAL Cases Reported Since 1/22/20
28,456,860

NEW Cases Reported to CDC on 3/1/21
50,935

Change in 7-Day Case Average
+3.5%

Current 7-Day Case Average (2/23/21 - 3/1/21)
66,010

Prior 7-Day Case Average (2/16/21 - 2/22/21)
63,760

Peaks in New Cases and Highest 7-Day Moving Average

<table>
<thead>
<tr>
<th></th>
<th>Highest Daily Number of New Cases</th>
<th>Highest 7-Day Moving Average</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current</td>
<td>315,179 (1/8/21)</td>
<td>249,303 (1/11/21)</td>
</tr>
<tr>
<td>2nd Peak</td>
<td>75,119 (7/17/20)</td>
<td>67,316 (7/23/20)</td>
</tr>
<tr>
<td>1st Peak</td>
<td>42,550 (4/6/20)</td>
<td>31,936 (4/12/20)</td>
</tr>
</tbody>
</table>

Reported 7-day moving average of COVID-19 cases has decreased 74% since January 11, 2021
New Admissions of Patients with Confirmed COVID-19
August 1, 2020 – February 28, 2021

Patients Currently Hospitalized with COVID on 2/28/21
41,413

New Admissions on 2/28/21
4,606

Peak in New Admissions (1/5/21)
18,008

Change in 7-Day Average of New Admissions
-11.9%

Current 7-Day Average of New Admissions (2/22/21 - 2/28/21)
5,755

Prior 7-Day Average of New Admissions (2/15/21 - 2/21/21)
6,529

Reported 7-day moving average of hospitalizations has decreased 65% since January 9, 2021
Daily Change in COVID-19 Deaths, United States
January 22, 2020 – March 1, 2021

TOTAL Deaths Reported Since 1/22/2020
513,122

NEW Deaths Reported to CDC on 3/1/21
1,283

Change in 7-Day Death Average
+2.2%

Current 7-Day Death Average (2/23/21 - 3/1/21)
2,009

Prior 7-Day Death Average (2/16/21 - 2/22/21)
1,967

Forecasted Total Deaths by 3/20/21
526,000-548,000
WEAR A MASK

STAY 6 FEET APART

AVOID CROWDS

AVOID TRAVEL
# Selected SARS-CoV-2 Variants

<table>
<thead>
<tr>
<th>Lineage</th>
<th>Characteristics</th>
</tr>
</thead>
</table>
| **B.1.1.7** (originally United Kingdom) | - Increased transmissibility  
                            - Possibly increased disease severity  
                            - Covered well by currently authorized vaccines |
| **B.1.351** (originally South Africa)      | - Possibly increased transmissibility  
                            - Moderately to severely reduced vaccine efficacy for some vaccines  
                            - *In vitro* studies suggest neutralization by certain monoclonal antibodies may be severely reduced |
| **P.1** (originally Brazil)                | - Preliminary reports of increased transmissibility  
                            - Antibodies elicited by previous infection or vaccine may be less effective |
| **B.1.427/B.1.429** (originally California) | - Preliminary reports of increased transmissibility and disease severity |
| **B.1.526** (originally New York)          | - Variable loss of neutralizing activity by some monoclonal and vaccine-induced antibodies |
Selected Vaccination Strategies to Address SARS-CoV-2 Variants

- Ramp up vaccination with 1st and 2nd doses of current EUA vaccines
- Booster doses
- Variant-specific vaccines
- Pan-CoV “universal” vaccines
Pfizer/Biontech COVID-19 Vaccine: Neutralizing Antibody Titers After First and Second Dose

*50% SARS-CoV-2–neutralizing geometric mean titers at 30 μg dose

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

P Wang, DD Ho et al.
Pfizer-Biontech Booster Study

- 3rd dose (30 µg) of Pfizer-Biontech COVID-19 vaccine, BNT162b2, will be given to participants in phase 1 trial to evaluate safety, tolerability and immunogenicity.

- Study will evaluate up to 144 participants in two age cohorts, 18-55 and 65-85 years of age.
Modern to begin clinical trials of COVID booster shots for variant from South Africa, sends to NIH for study
Variant Vaccine Strategy – Upcoming NIAID Clinical Trial in Collaboration with Moderna

- Moderna has developed a variant-specific vaccine candidate mRNA-1273.351 against the variant known as B.1.351 first identified in the Republic of South Africa.

- NIAID and Moderna will conduct a phase 1 study of the safety and immunogenicity of mRNA-1273.351 in naïve and previously vaccinated adults.

- Planned study launch: mid-March 2021
The “Holy Grail” – A Universal Coronavirus Vaccine

Universal Coronavirus Vaccines: The Time To Start Is Now
LT Giurgea, A Han and MJ Memoli

A Universal Coronavirus Vaccine
WC Koff and SF Berkley

Variant-Proof Vaccines – Invest Now for the Next Pandemic
DR Burton and EJ Topol
Question for @WHCOVIDResponse:

What is considered “fully vaccinated” after receiving the Johnson & Johnson vaccine?

We know with the other two it’s considered “second dose plus two weeks.”

When does protection kick in with J & J?

11:29 AM · Mar 1, 2021 · Twitter for iPhone